| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/18/2011 | EP2322165A1 Apo2 ligand/TRAIL formulations |
| 05/18/2011 | EP2322160A1 Methods of inducing terminal differentiation |
| 05/18/2011 | EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 05/18/2011 | EP2322143A1 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| 05/18/2011 | EP2321645A1 Susceptibility to hsp90-inhibitors |
| 05/18/2011 | EP2321640A1 Formulation for oral administration of proteins |
| 05/18/2011 | EP2321411A1 Melk epitope peptides and vaccines containing the same |
| 05/18/2011 | EP2321346A1 Methods and substances for stimulating muscle regeneration |
| 05/18/2011 | EP2321345A1 Multi-specific binding proteins targeting b cell disorders |
| 05/18/2011 | EP2321344A2 New insulin analogues of prolonged activity |
| 05/18/2011 | EP2321342A2 Combination therapy of hiv fusion/entry inhibitors targeting gp41 |
| 05/18/2011 | EP2321012A1 Organoarsenic compounds and methods for the treatment of cancer |
| 05/18/2011 | EP2320948A1 Methods for treating reperfusion injuries |
| 05/18/2011 | EP2320939A1 Tissue kallikrein for the treatment of parkinson's disease |
| 05/18/2011 | EP2320938A2 Use of human hyaluronidases for axonal regrowth |
| 05/18/2011 | EP2320937A2 Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
| 05/18/2011 | EP2320936A1 Prevention and treatment of radiation injury |
| 05/18/2011 | EP2320935A1 Soluble igf receptors as anti-angiogenic agents |
| 05/18/2011 | EP2320934A2 Methods of treating cognitive impairment |
| 05/18/2011 | EP2320933A1 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| 05/18/2011 | EP2320932A2 Methods of predicting cancer lethality using replikin counts |
| 05/18/2011 | EP2320931A2 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |
| 05/18/2011 | EP2320930A2 Treatment of inflammatory bowel diseases with mammal beta defensins |
| 05/18/2011 | EP2320929A2 Treatment of inflammatory diseases with mammal beta defensins |
| 05/18/2011 | EP2320928A2 Treatment of rheumatoid arthritis with mammal beta defensins |
| 05/18/2011 | EP2320927A2 Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| 05/18/2011 | EP2320926A2 Antiviral activity of the protein scytovirin and methods of use |
| 05/18/2011 | EP2320925A2 Complement antagonists and uses thereof |
| 05/18/2011 | EP2320924A1 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome |
| 05/18/2011 | EP2320923A2 Truncated analogues of glucose-dependent insulinotropic polypeptide |
| 05/18/2011 | EP2320882A1 A synthetic vaccine component |
| 05/18/2011 | EP2320751A2 Whey protein hydrolysate containing tryptophan peptide consisting of alpha lactalbumin and the use thereof |
| 05/18/2011 | EP2121742B1 Metastasis-specific peptides and their diagnostic and therapeutic applications |
| 05/18/2011 | EP2046821B1 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins |
| 05/18/2011 | EP2041161B1 Chiral compounds substituted with phosphonate ester or phosphonic acid |
| 05/18/2011 | EP1970379B1 Non-proteolysable oligopeptides that inhibit glycoprotein gp41 of hiv |
| 05/18/2011 | EP1960515B1 Anti-inflammatory peptides |
| 05/18/2011 | EP1909824B1 Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| 05/18/2011 | EP1797120B1 Deglycosylated and desialidated long pentraxin ptx3 |
| 05/18/2011 | EP1776133B1 Peptidic vasopressin receptor agonists |
| 05/18/2011 | EP1766011B1 Methods and uses of polypeptide ligands containing linkers |
| 05/18/2011 | EP1673457B1 Novel fungal proteins and nucleic acids encoding same |
| 05/18/2011 | EP1578938B1 Promotion of peroxisomal catalase function in cells |
| 05/18/2011 | EP1575867B1 Peptide nanostructures, methods for their preparation and use |
| 05/18/2011 | EP1558277B1 Treatment of inflammatory bowel disease |
| 05/18/2011 | EP1553967B1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 05/18/2011 | EP1494541B1 Canola protein isolate compositions |
| 05/18/2011 | EP1467969B1 Dna minor groove binding compounds |
| 05/18/2011 | EP1356298B1 Diagnosis of disease |
| 05/18/2011 | EP1268096B9 Extrusion die |
| 05/18/2011 | EP1238089B1 Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
| 05/18/2011 | EP1032595B1 Nucleic acids involved in the responder phenotype and applications thereof |
| 05/18/2011 | CN1982329B Biologically active peptide comprising tyrosyl-seryl-valine (YSV) and use thereof |
| 05/18/2011 | CN1961958B Method for improving cicatrisation of wound |
| 05/18/2011 | CN1642524B Site specific delivery of co-administered drugs via inhalation |
| 05/18/2011 | CN102066938A Method for determination of edema associated with liver disease |
| 05/18/2011 | CN102066559A Biotechnological production of cyanophycin dipeptides |
| 05/18/2011 | CN102066421A Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSK) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury |
| 05/18/2011 | CN102066416A Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 05/18/2011 | CN102066414A Recombinant FSH including alpha2,3- and alpha2,6-sialylation |
| 05/18/2011 | CN102066412A Treatment of diseases and conditions mediated by eicosanoids |
| 05/18/2011 | CN102066410A HLA-DR binding peptides and their uses |
| 05/18/2011 | CN102066406A Anti-angiogenic compositions and therapeutic applications thereof |
| 05/18/2011 | CN102066404A Angiogenic peptide |
| 05/18/2011 | CN102066402A Peptide derivative and composition for promoting tear secretion comprising the same |
| 05/18/2011 | CN102066399A Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
| 05/18/2011 | CN102066386A Boronate ester compounds and pharmaceutical compositions thereof |
| 05/18/2011 | CN102065929A Stimulation of cartilage formation using reduced pressure treatment |
| 05/18/2011 | CN102065899A Formulations of PEG-functionalised serine proteases with high concentrations of an aromatic preservative |
| 05/18/2011 | CN102065887A Site-directed modification of factor IX |
| 05/18/2011 | CN102065886A Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 05/18/2011 | CN102065885A Isoform-specific insulin analogues |
| 05/18/2011 | CN102065884A Pegylated insulin lispro compounds |
| 05/18/2011 | CN102065883A Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| 05/18/2011 | CN102065882A Osteogenic composition including a complex growth factor/amphiphilic polymer, a soluble cation salt, and an organic substrate |
| 05/18/2011 | CN102065881A Stable amyloid BETA monomers and oligomers |
| 05/18/2011 | CN102065880A Immunotherapies employing self-assembling vaccines |
| 05/18/2011 | CN102065844A Dry transglutaminase composition |
| 05/18/2011 | CN102065841A Treatment of bladder dysfunction using liposomal botulinum toxin |
| 05/18/2011 | CN102065686A Use of ferritin to treat iron deficiency disorders |
| 05/18/2011 | CN102061306A Preparation method and application of immunomodulatory peptide |
| 05/18/2011 | CN102061291A Lysozyme as well as preparation and application thereof |
| 05/18/2011 | CN102060929A T-cell immune balance peptide |
| 05/18/2011 | CN102060928A Bombesin-oriented anti-tumor polypeptide and preparation method and application thereof |
| 05/18/2011 | CN102060921A High-stability VPAC2 type receptor specific activator MHDBAY, preparation method and application thereof |
| 05/18/2011 | CN102060920A Construction of abrin A chain mutant and application as candidate vaccine antigen |
| 05/18/2011 | CN102060917A Recombinant staphylococcal enterotoxin M and application |
| 05/18/2011 | CN102060916A Enterotoxin C2 superantigen mutant proteins, and coding gene and preparation and application thereof |
| 05/18/2011 | CN102060915A Modifiable loca of human type 3 adenovirus hexon and application thereof |
| 05/18/2011 | CN102060913A Heptapeptide combined with human serum albumin and application thereof |
| 05/18/2011 | CN102060912A Amyloid protein oligomer conformation type epitope polypeptide and application thereof |
| 05/18/2011 | CN102060910A HLA (Human Leukocyte Antigen)-A*0201 limitation CTL (Cytotoxic T Lymphocyte) epitope of zinc translocator and application thereof |
| 05/18/2011 | CN102060909A Tumor specific target polypeptide and application thereof |
| 05/18/2011 | CN102060908A Novel synthetic antithrombotic polypeptide, and preparation method and application thereof |
| 05/18/2011 | CN102058878A Prosoma pellet tablet for generating allicin in stomach and preparation method thereof |
| 05/18/2011 | CN102058877A Pharmaceutical composition for osteoarthritis molding and preparation method thereof as well as molding method |
| 05/18/2011 | CN102058876A Cervix antibacterial repair complex and preparation method thereof |
| 05/18/2011 | CN102058875A Polypeptide drug for treating human condyloma acuminatum |
| 05/18/2011 | CN102058874A Polypeptide vaccine for treating tumors caused by human papillomavirus 16 |
| 05/18/2011 | CN102058873A Polypeptide drug for treating diseases caused by highly pathogenic avian influenza virus H5N1 |